Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism

Lobo, José Luís; Jiménez, David; Orue, Ma Teresa; Grau, E; Naufall, Dolores; Madridano, Olga; Monréal, Manuel

doi:10.1111/j.1365-2141.2007.06679.x

Cited by 19 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 11 This must, however, be considered against the annual risk of arterial thromboembolism in the absence of OAC therapy, which is 12% to 22% for patients with mechanical heart valves, and 6% to 18% in patients with AF plus a CHA 2 DS 2 -VASc score of ≥3, and there is a 5% to 7% risk of VTE recurrence in the first 3 months for patients receiving OAC for previous VTE. 40 – 43 The clinical consequences of a thrombotic or bleeding event must also be taken into consideration when deciding to restart OACs. For example, mechanical heart valve thrombosis is fatal in approximately 12% of patients, embolic stroke results in death in up to 27% of cases, while VTE has a case-fatality rate of approximately 4% to 14%, and major bleeding has a case-fatality rate of approximately 9% to 13%.…”

Section: Risk Stratification and Clinical Decision-makingmentioning

confidence: 99%

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

Milling

Spyropoulos

2016

The American Journal of Medicine

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant armamentarium, and provide an alternative to the use of vitamin K antagonists such as warfarin. Regardless of the type of agent used, bleeding is the major complication of anticoagulant therapy. The decision to restart oral anticoagulation following a major hemorrhage in a previously anticoagulated patient is supported largely by retrospective studies rather than randomized clinical trials (mostly with vitamin K antagonists), and remains an issue of individualized clinical assessment: the patient’s risk of thromboembolism must be balanced with the risk of recurrent major bleeding. This review provides guidance for clinicians regarding if and when a patient should be re-initiated on DOAC therapy following a major hemorrhage, based on the existing evidence.

show abstract

Section: Risk Stratification and Clinical Decision-makingmentioning

confidence: 99%

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

Milling

Spyropoulos

2016

The American Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…The risk of VTE recurrence is present even during anticoagulant therapy. An overall rate of 5.5% of recurrent VTE during the initial 3 months of anticoagulant treatment was found in one study [11] and of 7.0% in the very large cohort of patients included in the RIETE registry [16]; in the latter study patients with recurrence during VKA treatment were more frequently males, younger, and with a higher incidence of cancer than those without recurrence [16]. …”

Section: Incidence Of Vte Recurrencementioning

confidence: 99%

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Palareti¹

2012

Scientifica

View full text Add to dashboard Cite

Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has a strong tendency to recur. While VTE is an acute disease, it may have variable outcomes in early and late phases after initial presentation. Furthermore, the incidence of late, clinically important consequences (postthrombotic syndrome and/or chronic thromboembolic pulmonary hypertension) increases in case of recurrent events. The aims of the present review are (i) to analyze the incidence and risk factors for recurrence of VTE (either those related to the type of first thrombotic event or to the patients), the risks associated with occurrence of recurrent events, and the problems linked to the diagnosis, not always easy, of recurrent events; (ii) to discuss whether or not it is possible to predict the individual risk of recurrence after a first event, by stratifying patients at high or low risk of recurrence, and how this can influence their treatment; (iii) to comment what the current guidelines and guidance suggest/recommend about anticoagulant treatment after a first VTE event and, finally, to propose practical indications on how to manage individual patients affected by VTE.

show abstract

“…According to the Virchow's triad, VTE is a condition that results from altered blood coagulation, stasis or abnormalities in the vessel wall [11,12]. Previous studies have identified multiple risk factors for VTE, including age, previous VTE episodes and cerebrovascular disease (CVA) [13][14][15]. Diabetes, leg fractures, major surgery and certain cancers are also associated with increased risk of VTE [16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Multiple sclerosis increases the risk of venous thromboembolism: a nationwide cohort analysis

Chung

Lin

Tsai

et al. 2015

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism

Abstract: must be at least some other mechanisms platelet dysfunction that influence the risk of bleeding. As long as the molecular mechanisms of dysplasia and dysfunction of platelets in MDS are unknown, we can only rely on platelet counts.

Cited by 19 publications

References 10 publications

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Multiple sclerosis increases the risk of venous thromboembolism: a nationwide cohort analysis

Contact Info

Product

Resources

About